Novartis tests new weapon against tough breast cancers

NCT ID NCT06726148

Recruiting now Disease control Sponsor: Novartis Pharmaceuticals Source: ClinicalTrials.gov ↗

Summary

This study is testing a new drug called ECI830 for people with advanced breast cancer that has stopped responding to standard hormone therapies. Researchers want to see if ECI830 is safe and effective when given alone or combined with two existing cancer drugs. The trial will enroll about 280 adults whose cancer has specific genetic features and has progressed after prior treatments.

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••
Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

Dana Farber Cancer Institute
RECRUITING

Boston, Massachusetts, 02115, United States

Contact

Contact Phone: •••-•••-•••• Email: •••••@•••••
Florida Cancer Specialists
RECRUITING

Fort Myers, Florida, 33901, United States

Contact

Contact Phone: •••-•••-•••• Email: •••••@•••••
Fred Hutch Cancer Research
RECRUITING

Seattle, Washington, 98109, United States

Contact Phone: •••-•••-•••• Email: •••••@•••••

Contact
MD Anderson Cancer Center Uni of Te
RECRUITING

Houston, Texas, 77030, United States

Contact Phone: •••-•••-•••• Email: •••••@•••••

Contact
Memorial Sloan Kettering
RECRUITING

New York, New York, 10017, United States

Contact Email: •••••@•••••

Contact
Novartis Investigative Site
RECRUITING

Clayton, Victoria, 3168, Australia
Novartis Investigative Site
RECRUITING

Melbourne, Victoria, 3004, Australia
Novartis Investigative Site
RECRUITING

Toronto, Ontario, M5G 2M9, Canada
Novartis Investigative Site
RECRUITING

Montreal, Quebec, H4A 3J1, Canada
Novartis Investigative Site
RECRUITING

Brno, 656 53, Czechia
Novartis Investigative Site
RECRUITING

Copenhagen, DK-2100, Denmark
Novartis Investigative Site
RECRUITING

Odense C, 5000, Denmark
Novartis Investigative Site
RECRUITING

Bordeaux, 33076, France
Novartis Investigative Site
RECRUITING

Saint-Herblain, 44805, France
Novartis Investigative Site
RECRUITING

Freiburg im Breisgau, Baden-Wurttemberg, 79106, Germany
Novartis Investigative Site
RECRUITING

Heidelberg, 69120, Germany
Novartis Investigative Site
RECRUITING

Ulm, 89081, Germany
Novartis Investigative Site
RECRUITING

Haifa, 3109601, Israel
Novartis Investigative Site
RECRUITING

Tel Aviv, 6423906, Israel
Novartis Investigative Site
RECRUITING

Modena, MO, 41124, Italy
Novartis Investigative Site
RECRUITING

Milan, 20141, Italy
Novartis Investigative Site
RECRUITING

Chuo Ku, Tokyo, 1040045, Japan
Novartis Investigative Site
RECRUITING

Singapore, 119074, Singapore
Novartis Investigative Site
RECRUITING

Seoul, Korea, 03080, South Korea
Novartis Investigative Site
RECRUITING

Barcelona, 08035, Spain
Novartis Investigative Site
RECRUITING

Barcelona, 08036, Spain
Novartis Investigative Site
RECRUITING

Tainan, 704, Taiwan
Novartis Investigative Site
RECRUITING

London, Oxford, OX3 7LE, United Kingdom
SCRI Oncology Partners
RECRUITING

Nashville, Tennessee, 37203, United States

Contact

Contact Email: •••••@•••••
University of California LA
RECRUITING

Los Angeles, California, 90095, United States

Contact Phone: •••-•••-•••• Email: •••••@•••••

Contact
WA Uni School Of Med
RECRUITING

St Louis, Missouri, 63110, United States

Contact

Contact Phone: •••-•••-•••• Email: •••••@•••••

Conditions

Explore the condition pages connected to this study.

ADVANCED CCNE1-AMPLIFIED SOLID TUMORS ADVANCED HR+/HER2- BREAST CANCER